Treatment Evaluation of Melasma Patients in Dr. Hasan Sadikin General Hospital Bandung in period of 2013–2014

Authors

  • Ayu Adzani Sabila
  • Reti Hindritiani
  • Dimas Erlangga Luftimas

Keywords:

Evaluation, melasma, treatment

Abstract

Background: Melasma is hyperpigmentation of the skin especially located on face exposed to the sunlight. This condition was characterized by brown to gray-brown macula with irregular border. Difficulties in treatment of melasma arise from high tendency for relapse, expensive cost, and high risk of side effects such as erythema, sores, scales, and acne eruption. Study about evaluation of melasma therapy in Dr. Hasan Sadikin General Hospital Bandung have not ever been done before. Therefore, this study was conducted to evaluate therapy of melasma in the Policlinic of Dermatology and Venereology, Dr. Hasan Sadikin General Hospital Bandung.

Methods: This study was retrospectively descriptive. Data were obtained from the new melasma patient medical records of Policlinic of Dermatology and Venereology of Dr. Hasan Sadikin General Hospital Bandung in period of January 2013–2014. Sampling method used in this study was total sampling. Treatments of melasma were evaluated by using Melasma Area Severity Index (MASI) score. Collected data were processed and presented in frequency distribution and percentage.

Results: The most used topical drugs were combination of hydroquinone and tretinoin, and all of patients received sunblock. Most frequent time interval was two weeks (30.8%). The most common side effect was erythema (10 out of 22). Decreased MASI score was discovered in 48.1% and the most decreased category was mild (14 out of 25).

Conclusions: The very common topical drugs used are hydroquinone and tretinoin. The side effect of the treatment is Erythema. The decreased MASI score is mild. [AMJ.2016;3(4):610–5]


DOI: 10.15850/amj.v3n4.947

Downloads

Published

2017-01-11

Issue

Vol. 3 No. 4 (2016)

Section

Articles

License

  1. Authors retain copyright and grant Althea Medical Journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to freely share and remix the work with an acknowledgement of the work's authorship and initial publication in Althea Medical Journal. Althea Medical Journal is licensed under CC BY-NC 4.0
  2. Authors are permitted to copy and redistribute the journal's published version of the work non-commercially (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in Althea Medical Journal.